Advertisement

Related Videos

Peter Clark, MA, MD, FRCP: A Payer Perspective

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Advertisement

Advertisement




Oct
07
Today In Oncology
Residual Ovarian Cancer Risk in BRCA Carriers May Inform Timing of Preventive Surgery
The Molecular Watchman Why Measurable Residual Disease Testing Is Redefining Treatment and Surveillance in Colorectal and Bladder Cancers
Tile-Based Radiation Outperforms Postoperative Stereotactic Radiation Therapy in Resected Brain Metastases
Replacing Intensive Chemotherapy With Blinatumomab Improves Outcomes in High-Risk Pediatric Acute Lymphoblastic Leukemia
Pediatric and Adolescent Colorectal Carcinoma: A Retrospective Analysis
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo